Drugs / Acellbia
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02744196 | Jan 2015 → Feb 2017 | rheumatoid arthritis | Biocad | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Acellbia | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02744196 ↗ |
| Modality | Monoclonal antibody | “monoclonal antibody” NCT02744196 ↗ |
| Route | Intravenous | “600 mg as a slow intravenous infusion” NCT02744196 ↗ |